Actively Recruiting
Evaluating DT-101 Compared to Placebo for Adults with Major Depressive Disorder Receiving Medication
Led by Draig Therapeutics Ltd · Updated on 2026-10-14
118
Participants Needed
23
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying a drug called DT-101 to see if it can help adults with Major Depressive Disorder MDD, a form of depression. This clinical trial compares DT-101 with a placebo, which looks like the drug but contains no medicine. The study aims to evaluate the effect of DT-101 on depression symptoms in adults already receiving medication for depression. Participants will be randomly assigned to receive either DT-101 or placebo for 8 weeks. Before joining, they will have physical and neurological exams, blood and urine tests, clinical assessments, and a review of their medical and treatment history. During the 8-week treatment, these tests and assessments continue regularly to monitor participants and collect data on how DT-101 affects their depression. Blood samples will also be taken to understand how the body absorbs and uses DT-101. Throughout the study, participants will attend clinic visits for health checks and to complete questionnaires. Researchers will measure changes in depression severity using the Montgomery sberg Depression Rating Scale MADRS over 56 days. They will also evaluate safety and tolerability, along with other clinical assessments. The total participation time is about 8 weeks, with ongoing monitoring to ensure safety and collect study data.
CONDITIONS
Brief Title
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
Research Team
A
Aeron-1 Clinical Team
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here